U.S. FDA Approves TECVAYLI (Teclistamab-Cqyv), The First Bispecific T-Cell Engager Antibody For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma'

Press/Media

Period25 Oct 2022

Media coverage

85

Media coverage